1Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine [J].Structure, 1999, 7(2):169-177.
2Shrive AK, Cheetham GM, Holden D, et al. Three dimensional structure of human C-reactive protein [J]. Nat Struct Biol, 1996, 3(4):346-354.
3Black S, Kushner I, Samols D. C-reactive Protein [J]. J Biol Chem, 2004,279(47):487-490.
4Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule [J]. QJM, 2003, 96(11):793-807.
5Jabs WJ, Logering BA, Gerke P, et al. The kidney as a second site of human C-reactive protein formation in vivo[J]. Eur J Immunol, 2003, 33(1):152- 161.
6Mold C, Rodic-Polic B, Du Clos TW. Protection from Streptococcus pneumoniae infection by C- reactive protein and natural antibody requires complement but not Fcγ receptors[J]. J Immunol, 2002,168 (12):6375-6381.
7Volanakis JE. Human C- reactive protein: expression, structure, and function[J]. Mol Immunol, 2001, 38 (2-3) : 189- 197.
8Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation [J]. Clin Immunol, 2005, 117(2):104-111.
9Bodman-Smith KB, Melendez AJ, Campbell I, et al. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcγRI)[J]. Immunology, 2002, 107 (2):252- 260.
10Gershov D, Kim S, Brot N, et al. C-reactive protein binds to apoptotie cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response ; implications for systemic autoimmunity[J]. J ExpMed, 2000, 192(9) :1353-1364.
同被引文献11
1KANAPARTHY R, KANAPARTHY A, MAHENDRA M. C - re- active protein as a marker of periodontal disease [J]. Gen Dent, 2012, 60(1): e1 -e5.
2BELIBASAKIS G N. Microbiological and immune - pathological aspects of peri - implant disease[J]. Arch Oral Biol, 2014, 59 (1) : 66 -72.
3QUIRYNEN M, DE SOETE M, VAN STEENBERGHED D. In- fectious risks for oral implants: a review of the literature[ J]. Clin Oral Implants Res, 2002, 13 ( 1 ) : 102 - 109.
4PETKOVIC A B, MATIC S M, STAMATOVIC N V, et al. Proin- flammatory cytokines ( IL - 1β and TNF -α) and chemokines ( IL - 8 and MIP - 1α) as markers of peri - implant tissue condition [ J]. Int J Oral Maxillofac Surg, 2010, 39(5) : 478 -485.
5JACOBI GRESSER E, HUESKER K, SCHUTT S. Genetic and immunological markers predict titanium implant failure: a retrospective study[J]. Int J Oral Maxillofac Surg, 2013, 42(4) : 537 -543.
6ARAKAWA H, UEHARA J, HARA ES, et al. Matrix metallopro- teinase - 8 is the major potential collagenase in active peri - impla- ntitis[J]. J Pros Res, 2012, 56(4) : 249 -255.
7GUNCU G N, AKMAN A C, GUNDAY S, et al. Effect of inflam- mation on cytokine levels and bone remodelling markers in peri - implant sulcus fluid : A preliminary report [ J ]. Cytokine, 2012, 59(2) : 313 -316.
8BLACK S, KUSHNER I, SAMOLS D. C -reactive Protein[J]. J Biol Chem, 2004, 279(47) : 487 -490.
9HIRSCHFIELD G M, PEPYS M B. C -reactive protein and cardi- ovascular disease: new insights from an old molecule[ J]. Q J M, 2003, 96 ( 11 ) : 793 - 807.
10VENZA I, VISALLI M, CUCINOTTA M, et al. Proinflammatory gene expression at chronic periodontitis and peri - implantitis sites in patients with or without type 2 diabetes [ J ]. J Periodontol, 2010, 81(1) : 99-108.
